ENHANCEMENT OF BYSTANDER EFFECTS WITH THE COMBINATION OF IMMUNO-GENE THERAPY AND PRO-DRUG GENE THERAPY
ENHANCEMENT OF BYSTANDER EFFECTS WITH THE COMBINATION OF IMMUNO-GENE THERAPY AND PRO-DRUG GENE THERAPY
批准号:
13671653
负责人:
KUMON Hiromi
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In this research, enhancement of bystander effects with the combination of immuno-gene therapy and pro-drug gene therapy was analyzed. As a main portion of this project, effects of UPRT (uracil phosphoribosyltransferase) gene therapy (new type of pro-drug gene therapy) for bladder cancer was analyzed. Here we show the summary of them.Objective : We evaluated whether adenovirus-mediated UPRT genes could generate sensitized antitumor effect of 5-FU on experimental bladder cancer.Material and Method : Human bladder cancer cell T24 was used for in vitro and in vivo study. Two recombinant replication-deficient adeno virus vectors, AdCA-LacZ and AdCA-UPRT, were constructed from a serotype 5 wild-type adenovirus (Ad5) by inserting CAG promoter with an E. coli LacZ gene and an E. coli UPRT gene, respectively, into the EIA region of the genome, deleting the E1B and E3 region. For in vitro chemosensitivity assay, T24 cells were seeded in 96-well plates at a density of 1000 cells/well, infected w … More ith AdCA-LacZ or AdCA-UPRT (MOI :0-100), and then exposed to 5-FU. Six days later, the sensitivity was assessed with MTT assay. For in vivo tumor treatment, subcutaneous tumors were employed by injection of T24 cells (10^7 cells). Twelve days after tumor cell injection (day 12) when tumor becomes palpable with mean estimated weight 147mg (108 -199mg), mouse were randomized to be directly injected with AdCA-LacZ or AdC A-UPRT (1X10^8 pfu/10ul) subsequently (two days later : day14) with either saline or 5-FU(2Omg/kg) intraperitoneally for 10days (from day14 to 23).Results : AdCA-UPRT infection increased the sensitivity of T24 cells to 5-FU in a MOI-dependent manner. IC50 to 5-FU shifted from 5,М in, control cells to 0.05М in AdCA-UPRT-infected cells at MOI of 50 indicating 100 fold sensitization by AdCA-UPRT infection. Consistent with in vitro studies, administration of AdCA-UPRT into the tumor of T24 cells, together with systemic 5-FU administration, resulted in sup pression of tumor growth at day28, compared with the control tumor groups : Among control groups, difference was not observed in comparis on with the presence or absence of 5-FU administrationConclusion : These results suggest that UPRT gene therapy with 5-FU can sensitize the antitumor effect of 5-FU. Consequently, this approach is a new chemosensitizing strategy for cancer gene therapy and a more feasible modality for the treatment of bladder cancer. Less
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
那須保友, 公文裕巳: "前立腺癌遺伝子治療の現状と展望"岡山医学会雑誌. 114. 173-177 (2002)
Yasutomo Nasu、Hiromi Kumon:“前列腺癌基因治疗的现状和前景”冈山医学会杂志 114. 173-177 (2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
T.Kurashige: "NY-ESO-1 expression and immunogenicity, associated with transitional cell carcinoma : Correlation with tumor grade 1"Cancer Research. 61. 4671-4674 (2001)
T.Kurashige:“NY-ESO-1 表达和免疫原性与移行细胞癌相关:与肿瘤 1 级的相关性”癌症研究。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kraaji R.: "Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice"Lab Anim. 36(2). 165-172 (2002)
Kraaji R.:“小鼠原位前列腺肿瘤经直肠超声容量测定的验证”实验室动画。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Y, Nasu: "Combination, gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer."Prostate Cancer and Prostatic Diseases. 4. 44-55 (2001)
Y,Nasu:“在前列腺癌原位小鼠模型中使用腺病毒载体介导的 HSV-tk GCV 和 IL-12 进行组合基因治疗。”前列腺癌和前列腺疾病。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
那須保友: "前立腺癌遺伝子治療の現状と展望"岡山医学会雑誌. 114. 173-177 (2002)
Nasu Yasutomo Nasu:“前列腺癌基因治疗的现状和前景”冈山医学会杂志 114. 173-177 (2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 14 条
Investigation of the mechanisms of personalized-cancer vaccination by REIC/Dkk-3 based gene therapy.
-
批准号:23390382
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.81万
-
财政年份:2011
-
负责人:KUMON Hiromi
-
依托单位:
Development of novel methods for identifying antibiofilm agents against multidrug-resistant Acinetobacter baumannii
-
批准号:23659759
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:KUMON Hiromi
-
依托单位:
The molecular function of immortalization-related genes in the regulation of Oncogenic Ras and prostatic carcinogenesis.
-
批准号:20390426
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.23万
-
财政年份:2008
-
负责人:KUMON Hiromi
-
依托单位:
DEVELOPMENT OF TAILORED-MADE TYPE PROSTATE CANCER GENE THERAPY AIMING AT SYSTEMIC IMMUNE-ACTIVATION
-
批准号:15209052
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$26.54万
-
财政年份:2003
-
负责人:KUMON Hiromi
-
依托单位:
Development of non invasive lower urinary tract function test using ultrasound Doppler imaging
-
批准号:13557135
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$5.57万
-
财政年份:2001
-
负责人:KUMON Hiromi
-
依托单位:
Analysis of expression and function of vacuolar-type H^+-ATPase at bladder
-
批准号:08457424
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.03万
-
财政年份:1996
-
负责人:KUMON Hiromi
-
依托单位:
The Role of Fimbriae of Escherichia coli in Genitourinary Tract Infection.
-
批准号:02670708
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$0.83万
-
财政年份:1990
-
负责人:KUMON Hiromi
-
依托单位: